Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 4;26(3):584-586.
doi: 10.1093/neuonc/noad237.

Associations between recurrence patterns and outcome in glioblastoma patients undergoing re-resection: A complementary report of the RANO resect group

Philipp Karschnia  1   2 , Antonio Dono  3 , Jacob S Young  4 , Stephanie T Juenger  5 , Nico Teske  1   2 , Levin Häni  6 , Tommaso Sciortino  7 , Christine Y Mau  8 , Francesco Bruno  9 , Luis Nunez  10 , Ramin A Morshed  4 , Alexander F Haddad  4 , Michael Weller  11 , Martin van den Bent  12 , Niklas Thon  1   2 , Juergen Beck  6 , Shawn Hervey-Jumper  4 , Annette M Molinaro  4 , Nitin Tandon  3 , Roberta Rudà  9 , Michael A Vogelbaum  8 , Lorenzo Bello  7 , Oliver Schnell  6 , Stefan J Grau  5   13 , Susan M Chang  4 , Mitchel S Berger  4 , Yoshua Esquenazi  3 , Joerg-Christian Tonn  1   2
Affiliations

Associations between recurrence patterns and outcome in glioblastoma patients undergoing re-resection: A complementary report of the RANO resect group

Philipp Karschnia et al. Neuro Oncol. .
No abstract available

Keywords: glioblastoma; localization; outcome; re-resection; recurrence.

PubMed Disclaimer

Conflict of interest statement

M.W.—Research grants: Quercis, Versameb. Honoraria or advisory board participation and consulting: Bayer, Curevac, Medac, Neurosense, Novartis, Novocure, Orbus, Philogen, Roche, Servier. M.v.d.B.—Consultant: Servier, Boehringer Ingelheim, Carthera, Nerviano, Genenta, Astra Zeneca, Fore Biotherapeutic, Incyte, Chimerix, Roche. N.T.—Research grant: Medtronic. Founder: BrainDynamics; Advisory Board: Nervonik, BrainGrade. R.R.—Honoraria, advisory board, and consulting: UCB, Bayer, Novocure, Genenta, Servier. M.A.V.—Indirect equity and patent royalty interests: Infuseon Therapeutics. Honoraria: Chimerix, Midatech. Research grants: DeNovo Pharma, Oncosynergy, Infuseon, Chimerix. J.-C.T.—Research grants: Novocure, Munich Surgical Imaging. Advisory board: AAA Novartis. Royalties: Springer Publisher. P.K.; A.D.; J.S.Y.; S.T.J.; N.Te.; L.H.; T.S.; C.Y.M.; F.B.; L.N.; R.A.M.; A.F.H.; N.Th.; J.B.; S.H.J.; A.M.M.; L.B.; O.S.; S.J.G.; S.M.C.; M.S.B.; Y.E.—None.

Figures

Figure 1.
Figure 1.
Recurrence patterns and outcome in glioblastomas undergoing re-resection. (A) Patterns of first recurrence for patients with a previously resected glioblastoma. (B) Initial tumor location (“dominant”: dominant hemisphere), time to first recurrence, and pre- as well as postoperative CE tumor volumes stratified according to the recurrence patterns. (C) Postoperative Karnofsky Performance Status and non-surgical therapies following re-resection stratified according to the recurrence patterns. (D) Kaplan–Meier estimates of overall survival after re-resection for patients with progressive residual CE tumor (n = 50), recurrence bordering the resection cavity (n = 187), distant recurrences (n = 45), and multiple recurrence patterns (n = 27). Points indicate deceased or censored patients, light shading indicates SEM.
See this image and copyright information in PMC

References

    1. Karschnia P, Dono A, Young JS, et al. . Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: a report of the RANO resect group. Neuro Oncol. 2023;25(9):1672–1685. - PMC - PubMed
    1. Suchorska B, Weller M, Tabatabai G, et al. . Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial. Neuro Oncol. 2016;18(4):549–556. - PMC - PubMed
    1. Louis DN, Perry A, Wesseling P, et al. . The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–1251. - PMC - PubMed
    1. Drumm MR, Dixit KS, Grimm S, et al. . Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas. Neuro Oncol. 2020;22(4):470–479. - PMC - PubMed
    1. Venkataramani V, Yang Y, Schubert MC, et al. . Glioblastoma hijacks neuronal mechanisms for brain invasion. Cell. 2022;185(16):2899–2917.e31. - PubMed